Specify a stock or a cryptocurrency in the search bar to get a summary
Turnstone Biologics Corp. Common Stock
TSBXTurnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California. Address: 9310 Athena Circle, La Jolla, CA, United States, 92037
Analytics
WallStreet Target Price
2.42 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures TSBX
Dividend Analytics TSBX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TSBX
Stock Valuation TSBX
Financials TSBX
Results | 2019 | Dynamics |